A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status:
Enrolling by invitation
Trial end date:
2027-01-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect long-term safety and efficacy data for participants
treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are
currently enrolled in ibrutinib studies that have been completed according to the parent
protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from
ibrutinib treatment.